| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
WWL-123 targets α/β-hydrolase domain-containing protein 6 (ABHD6), a serine hydrolase that hydrolyzes the endocannabinoid 2-arachidonoylglycerol (2-AG). ABHD6 is one of the principal enzymes responsible for regulating 2-AG levels in the brain. By inhibiting ABHD6, WWL-123 increases 2-AG levels, modulating endocannabinoid signaling. ABHD6 has also been implicated in neurological disorders, inflammation, and metabolic diseases. WWL-123 is a selective inhibitor with an IC₅₀ of 430 nM.
|
|---|---|
| ln Vitro |
WWL-123 inhibits ABHD6 with an IC₅₀ of 430 nM. It shows selectivity for ABHD6 over other serine hydrolases. The compound crosses the blood-brain barrier and inhibits ABHD6 in brain parenchyma. WWL-123 exerts antiepileptic effects in PTZ-induced epileptiform seizures and spontaneous seizures in R6/2 mice. These activities make it a valuable tool for studying ABHD6 biology and endocannabinoid signaling.
|
| ln Vivo |
WWL-123 exerts antiepileptic effects in vivo, suppressing seizures in both PTZ-induced and R6/2 mouse models. It crosses the blood-brain barrier and inhibits ABHD6 in brain parenchyma. The compound's in vivo efficacy in seizure models demonstrates its potential for studying neurological disorders and endocannabinoid signaling. Specific dosing and efficacy details are documented in the literature.
|
| Enzyme Assay |
The non-cellular enzyme/receptor binding assay for WWL-123 typically involves measuring ABHD6 enzymatic activity using a fluorogenic substrate. Recombinant ABHD6 enzyme is incubated with a suitable substrate (e.g., a fluorogenic ester) and varying concentrations of WWL-123. The release of fluorescent product is measured over time. IC₅₀ values are calculated from dose-response curves. Selectivity over other serine hydrolases is assessed using similar assays with panels of related enzymes.
|
| Cell Assay |
In vitro cellular assays for WWL-123 typically use neuronal cell lines or primary neurons to evaluate ABHD6 inhibition. Cells are treated with various concentrations of WWL-123, and ABHD6 activity is assessed by measuring the hydrolysis of a fluorogenic substrate or by quantifying 2-AG levels using LC-MS/MS. Cell viability is assessed using MTT or LDH assays. The compound's effects on endocannabinoid signaling can be evaluated by measuring downstream signaling markers.
|
| Animal Protocol |
In vivo animal studies for WWL-123 have demonstrated antiepileptic efficacy in PTZ-induced seizure models and in R6/2 mice (a model of Huntington's disease). WWL-123 is administered intraperitoneally or orally. Seizure incidence, latency, and severity are monitored. Brain tissue is collected to measure ABHD6 inhibition and 2-AG levels. Behavioral assessments are performed to evaluate neurological function. Detailed protocols are available in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of WWL-123 are characterized by its ability to cross the blood-brain barrier. As a small molecule with molecular weight 436.50, it is expected to have reasonable oral bioavailability. The compound is brain-penetrant, making it suitable for studying neurological disorders. Specific PK parameters such as half-life, Cmax, and protein binding are not extensively documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for WWL-123 are limited. As a research-grade compound, comprehensive toxicology studies are not available. The compound has been used in animal models at doses that exert antiepileptic effects without apparent acute toxicity. However, detailed toxicity profiles are not documented. Standard laboratory safety precautions should be observed when handling this compound.
|
| References |
|
| Additional Infomation |
WWL-123 is a research-grade compound intended for laboratory use only. It is not approved for clinical use as a therapeutic agent. Its primary applications include studying ABHD6 biology and endocannabinoid signaling, investigating the role of ABHD6 in neurological disorders including epilepsy and Huntington's disease, and exploring the therapeutic potential of ABHD6 inhibitors. WWL-123 is a valuable tool for neuroscience and drug discovery research.
|
| Molecular Formula |
C28H24N2O3
|
|---|---|
| Molecular Weight |
436.501767158508
|
| Exact Mass |
436.178
|
| CAS # |
1338575-41-9
|
| PubChem CID |
53364549
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
655.2±55.0 °C at 760 mmHg
|
| Flash Point |
350.1±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.631
|
| LogP |
5.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
639
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CC1=CC(=CC=C1)C2=CC=CC=C2)C(=O)OC3=CC=CC(=C3)C4=CC=C(C=C4)C(=O)N
|
| InChi Key |
QKMMESWNJMOPIF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H24N2O3/c1-30(19-20-7-5-10-24(17-20)21-8-3-2-4-9-21)28(32)33-26-12-6-11-25(18-26)22-13-15-23(16-14-22)27(29)31/h2-18H,19H2,1H3,(H2,29,31)
|
| Chemical Name |
[3-(4-carbamoylphenyl)phenyl] N-methyl-N-[(3-phenylphenyl)methyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~114.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2910 mL | 11.4548 mL | 22.9095 mL | |
| 5 mM | 0.4582 mL | 2.2910 mL | 4.5819 mL | |
| 10 mM | 0.2291 mL | 1.1455 mL | 2.2910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
